Table 3.
Summary of dosimetric evaluation.
| Sequential boost | SIB | Significant (ANOVA) | |||
|---|---|---|---|---|---|
| CMS | Helical TomoTherapy | TomoDirect | |||
| # violation EVboost coverage | 1 | 2 | 1 | 1 | No |
| # violation EVbreast coverage | 2 | 1 | 0 | 0 | No |
| # CI ≥ 50% | 0 | 9 | 3 | 5 | Yes (P = 0.0001) |
| Vol107 ipsilateral breast (cc) | 463.32 (139.50–724.95) | 230.47 (90.92–442.41) | 346.61 (118.29–605.28) | 365.15 (179.19–767.29) | Yes (P = 0.04) |
| Dmean heart left sided (Gy) | 3.04 (1.30–7.35) | 3.12 (1.61–7.66) | 2.97 (1.59–6.89) | 4.49 (1.84–8.95) | No |
| V5 heart left sided (%) | 9.61 (3.66–23.72) | 10.10 (4.29–24.70) | 9.91 (2.54–25.65) | 16.50 (4.82–27.27) | No |
| V20 heart left sided (%) | 3.65 (0.83–13.20) | 3.65 (0.81–13.28) | 2.85 (0.00–11.10) | 5.98 (0.65–15.32) | No |
| V30 heart left sided (%) | 2.55 (0.15–10.49) | 2.55 (0.04–10.60) | 1.44 (0.00–6.73) | 3.74 (0.32–11.79) | No |
| D2 heart right sided (Gy) | 2.04 (1.25–3.72) | 3.34 (1.17–9.52) | 1.85 (1.29–2.38) | 4.30 (1.11–11.52) | No |
| V20 ipsilateral lung (%) | 10.95 (6.63–16.48) | 11.15 (6.63–16.71) | 10.32 (0.00–13.84) | 11.33 (6.02–17.26) | No |
| V5 ipsilateral lung (%) | 20.89 (12.59–28.87) | 24.96 (12.66–47.32) | 21.89 (4.36–28.49) | 30.45 (16.42–61.51) | No |
| Dmean ipsilateral lung (Gy) | 6.26 (3.69–8.64) | 6.72 (3.73–9.20) | 6.13 (2.15–7.96) | 7.24 (4.85–11.14) | No |
| Dmean contralateral breast (Gy) | 0.36 (0.03–1.25) | 0.44 (0.14–1.45) | 1.17 (0.27–3.60) | 0.46 (0.18–0.56) | Yes (P = 0.01) |
| D2 contralateral breast (Gy) | 2.26 (0.16–12.93) | 2.39 (0.40–12.96) | 4.61 (0.86–19.46) | 1.19 (0.52–1.50) | No |
In case more than 1 value is given, the first number is the mean value; the numbers between brackets are the minimum and maximum values.
D2: near-maximum dose, as a surrogate for the point maximum dose as suggested in the ICRU Report 83 [21].